Acerta Pharma BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.acerta-pharma.com
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's SyndromeProlymphocytic Leukemia
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 306
- Registration Number
- NCT02029443
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath